Ranchi News Desk

DelveInsight Highlights Major Advances, Transformative Therapies, and 400+ Leading Players Wheeling the COVID-19 Clinical Trial Pipeline Landscape

 Breaking News
  • No posts were found

DelveInsight Highlights Major Advances, Transformative Therapies, and 400+ Leading Players Wheeling the COVID-19 Clinical Trial Pipeline Landscape

September 03
20:28 2023
DelveInsight Highlights Major Advances, Transformative Therapies, and 400+ Leading Players Wheeling the COVID-19 Clinical Trial Pipeline Landscape

The COVID-19 Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of COVID-19 treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the pipeline landscape and fostering the potential growth of COVID-19 therapeutic advancements.

 

Key Takeaways from the COVID-19 Pipeline Report

  • DelveInsight’s COVID-19 pipeline report depicts a robust space with 400+ active players working to develop 400+ pipeline therapies for COVID-19 treatment.
  • The leading companies working in the COVID-19 market include Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A., TC BioPharm, Syntax for Science, S.L, Shaperon, Renibus Therapeutics,  Quercis Pharma, Pharmenterprises, Pharmamel S.L., Orpheris, OPKO Health, Oncotelic Inc., Notitia Biotechnologies Company, Jazz Pharmaceuticals, Ionis Pharmaceuticals, Inotrem, Grifols Therapeutics LLC, Globavir Biosciences, Genentech, Inc., FSD Pharma, Faron Pharmaceuticals, Evergreen Therapeutics, Enlivex Therapeutics, Eiger BioPharmaceuticals, Direct Biologics, Debiopharm, Clene Nanomedicine, Chiesi Farmaceutici S.p.A., Cadila Healthcare Limited, Biotest, BeiGene, Apeiron Biologics, AgelessRx, AbbVie/Apotex, Telios Pharmaceuticals, Rapa Therapeutics, Organicell Regenerative Medicine, Miltenyi Biomedicine, MedRegen LLC, Kiadis Pharma, Kamada, Cellularity Incorporated, Bio-Thera Solutions, 3M,  Sironax, Pfizer, Oncovir, Ology Bioservices, Neutrolis, NeoImmune Tech, Natureceuticals Sdn Bhd, Medicine Invention, Kiadis Pharma, Grand Medical, Frontier Biotechnologies, Emergent Biosolutions, Codagenix, Cellenkos, AlloVir, Bausch Health Americas, AiCuris, AgenTus Therapeutics, 4D Pharma, and others.
  • Promising COVID-19 Pipeline Therapies in the various stages of development include AZD1222, 0.9% (w/v) saline, AZD7442, Plitidepsin 1.5 mg/day, Acalabrutinib, Sarilumab, rAd26-S, ZF2001, Bamlanivimab, AT-527, LY3819253, and others.
  • On January 2023, Guangzhou Patronus Biotech Co Ltd. announced a study of phase 3 clinical trials for Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 and ZF2001. A total of 1200 people aged 18 years and older who have completed two or three-dose inactivated COVID-19 vaccine for 6-18 months will be recruited in this study. Subjects will receive 1 dose at day 0 as a booster vaccination. Immunogenicity and safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 will be evaluated.
  • On February 2023, the National Vaccine and Serum Institute, China announced a study of Phase 2 clinical trials for Recombinant COVID-19 Vaccine (CHO cell, NVSI-06-09). A total of 516 healthy subjects aged 18 years and above who have been vaccinated with 2 doses/3 doses of inactivated COVID-19 vaccine, will be enrolled, and randomly assigned to experimental group and control group in a 1:1 ratio, with 258 subjects in each sequential group.
  • On April 2023, Shanghai Zerun Biotechnology Co.,Ltd announced a study of Phase 2 clinical trials for 202-CoV low adjuvant dose and 202-CoV standard dose. The purpose of this double-blind, randomized, controlled study is to assess immunogenicity and safety of 202-CoV at multiple dose levels, administered as 2 injections (i.m) at 28 days apart in adult subjects 18 years of age and above.
  • On July 2023, BioNTech SE announced a study of phase 2 & 3 clinical trials for BNT162b5 Bivalent (WT/OMI BA.2). The purpose of this clinical trial is to learn about the safety, tolerability and immunogenicity of BNT162b, RNA-based SARS-CoV-2 vaccine candidates given as a booster dose in adults to prevent COVID-19.

 

Request a sample and discover the recent advances in COVID-19 Treatment Drugs @ COVID-19 Infection Pipeline Report

 

The COVID-19 pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage COVID-19 drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the COVID-19 clinical trial landscape.

 

COVID-19 Overview

Coronavirus disease (COVID-19) is an infectious disease caused by the most recently discovered corona virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease causes respiratory illness (like the flu) with symptoms such as a cough, fever, and difficulty breathing.

 

Find out more about COVID-19 Treatment Drugs @ Drugs for COVID-19 Treatment

 

COVID-19 Emerging Drugs Profile

  • REGN-COV2: Regeneron Pharmaceuticals
  • Bucillamine: Revive Therapeutics
  • Mupadolimab (CPI-006): Corvus Pharmaceuticals
  • VERU‑111: Veru Inc.
  • Sarconeos (BIO101): Biophytis
  • Leronlimab: CytoDyn
  • Tocilizumab: Hoffmann-La Roche

 

COVID-19 Pipeline Therapeutics Assessment

The COVID-19 pipeline report proffers an integral view of the COVID-19 emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Learn more about the emerging COVID-19 Pipeline Therapies @ COVID-19 Clinical Trials Assessment

 

Scope of the COVID-19 Pipeline Report

  • Coverage- Global
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • COVID-19 Companies- Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A., TC BioPharm, Syntax for Science, S.L, Shaperon, Renibus Therapeutics,  Quercis Pharma, Pharmenterprises, Pharmamel S.L., Orpheris, OPKO Health, Oncotelic Inc., Notitia Biotechnologies Company, Jazz Pharmaceuticals, Ionis Pharmaceuticals, Inotrem, Grifols Therapeutics LLC, Globavir Biosciences, Genentech, Inc., FSD Pharma, Faron Pharmaceuticals, Evergreen Therapeutics, Enlivex Therapeutics, Eiger BioPharmaceuticals, Direct Biologics, Debiopharm, Clene Nanomedicine, Chiesi Farmaceutici S.p.A., Cadila Healthcare Limited, Biotest, BeiGene, Apeiron Biologics, AgelessRx, AbbVie/Apotex, Telios Pharmaceuticals, Rapa Therapeutics, Organicell Regenerative Medicine, Miltenyi Biomedicine, MedRegen LLC, Kiadis Pharma, Kamada, Cellularity Incorporated, Bio-Thera Solutions, 3M,  Sironax, Pfizer, Oncovir, Ology Bioservices, Neutrolis, NeoImmune Tech, Natureceuticals Sdn Bhd, Medicine Invention, Kiadis Pharma, Grand Medical, Frontier Biotechnologies, Emergent Biosolutions, Codagenix, Cellenkos, AlloVir, Bausch Health Americas, AiCuris, AgenTus Therapeutics, 4D Pharma, and others.
  • COVID-19 Pipeline Therapies- AZD1222, 0.9% (w/v) saline, AZD7442, Plitidepsin 1.5 mg/day, Acalabrutinib, Sarilumab, rAd26-S, ZF2001, Bamlanivimab, AT-527, LY3819253, and others.

 

Dive deep into rich insights for new drugs for COVID-19 treatment, Visit @ COVID-19 Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. COVID-19: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. REGN-COV2: Regeneron Pharmaceuticals
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. CNM-ZnAg: Clene Nanomedicine
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I)
  13. SIR1-365: Sironax
  14. Drug profiles in the detailed report…..
  15. Preclinical and Discovery Stage Products
  16. SB019: Novan
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. COVID-19 Key Companies
  20. COVID-19 Key Products
  21. COVID-19- Unmet Needs
  22. COVID-19- Market Drivers and Barriers
  23. COVID-19- Future Perspectives and Conclusion
  24. COVID-19 Analyst Views
  25. COVID-19 Key Companies
  26. Appendix

 

For further information on the COVID-19 pipeline therapeutics, reach out @ COVID-19 Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking